Drug Security Forum

The Evolution of the Procurement System: Global Trends and Technologies

02 Jun , 10:00–11:30
Drug Security Forum
Panel Session
Pavilion G, conference hall G2

Continuity of supply, and sufficiency of drugs for all citizens, including in situations of exponentially growing demand, are key to a country’s drug security. In turn, drug security depends on how effective the government drug procurement system is. Various mechanisms are used both in Russia and worldwide to lower procurement costs. These include long-term contracts, direct negotiations with manufacturers, and risk-sharing. All these can be considered as potential instruments for modernizing the current government procurement and drug supply system. Today, not all regions of the Russian Federation can solve the problem of drug deficits. One important strategy for ensuring adequate supplies may be a transition to a centralized procurement system. This would encourage planning and interregional distribution of drugs according to needs, improve the government’s negotiating position with regard to cost reduction, and increase patient coverage by the government. What factors dictate the need to modernize the current government procurement system? What international practices could be applied to optimize the current government procurement system from the point of view of preventing drug deficits in all regions of the Russian Federation? What impact might the establishment of a federal centre on planning and organizing drug supply have on citizen support, and on implementing the Healthcare National Project and other federal projects and programmes? What risks might centralizing drug supply carry, and will switching to a centralized procurement system help improve the country’s drug security? What supporting decisions in healthcare and related areas need to be made in order to successfully modernize the procurement system?

Vitaliy Omelyanovskiy, General Director, Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation

Elena Astapenko, Director, Department of Pharmaceutical Provision and Regulation of the Circulation of Medical Devices, Ministry of Health of the Russian Federation
Kirill Danishevskiy, Market Access Director, Takeda
Vitaly Dembrovsky, Director of Corporate Affairs for Healthcare and Public Health, Russia and Eurasia, AstraZeneca
Victor Dmitriev, General Manager, Association of Russian Pharmaceutical Manufacturers
Etleva Kadilli, Director, Supply Division, United Nations Children's Fund (UNICEF)
Timofey Nizhegorodtsev, Deputy Head, Federal Antimonopoly Service of the Russian Federation

Front row participants
Vadim Kukava, Executive Director, The Association of Pharmaceutical Companies «Innovative Pharma»
Airat Farrakhov, Deputy, Deputy Chairman of the Commission of the State Duma of the Federal Assembly of the Russian Federation for Support of the Development of Small- and Medium-sized Business
Alexey Fedorov, Expert, Russian "Union of Patients" Public Societies